Pfizer: This Is What Bulls Waited For

Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the massive earnings beat, with Pfizer on track to deliver at least $4.5 billion in net savings this year. Management showed extreme confidence by raising full-year EPS guidance, impressively absorbing a $0.20 charge from the strategic 3SBio deal to fuel future growth.